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Abstract
Introduction: We have previously demonstrated that ex vivo inhibition of costimulatory molecules on antigen-pulsed 
dendritic cells (DCs) can be useful for induction of antigen-specific immune deviation and suppression of autoimmune 
arthritis in the collagen induced arthritis (CIA) model. The current study evaluated a practical method of immune 
modulation through temporary systemic inhibition of the costimulatory molecule CD40.
Methods: Mice with collagen II (CII)-induced arthritis (CIA) were administered siRNA targeting the CD40 molecule. 
Therapeutic effects were evaluated by clinical symptoms, histopathology, Ag-specific T cell and B cell immune 
responses.
Results: Systemic administration of CD40-targeting siRNA can inhibit antigen-specific T cell response to collagen II, as 
well as prevent pathogenesis of disease in both a pre- and post-immunization manner in the CIA model. Disease 
amelioration was associated with suppression of Th1 cytokines, attenuation of antibody production, and upregulation 
of T regulatory cells.
Conclusions: These studies support the feasibility of transient gene silencing at a systemic level as a mechanism of 
resetting autoreactive immunity.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory and
deforming joint disease that affects approximately 1% of
adults. Although the precise etiology of RA has not been
clearly ascertained, numerous studies support the con-
cept that autoreactive T cells play a central role in the ini-
tiation and maintenance of the disease [1]. Advanced RA
is treated with TNF-α inhibitors such as Infliximab or
Embrel, however a significant proportion of patients do
not respond [2]. These patients have shown some
improvement following treatment with Abatacept, a clin-
ically approved CTLA4-Ig, which is believed to inhibit
antigen presenting cell (APC) co-stimulation of T cells by
high affinity binding to CD80/86 [3]. Clinical responses
induced by the co-stimulatory blockade support the
rationale for targeting this pathway. In addition to the
CD80/86-CD28 interaction, co-stimulation of T cell
responses occurs through the CD40-CD154 interaction
between APCs and T cells. CD40 signaling has been dem-
onstrated to be critical in the initiation and progression of
the rodent model of RA, collagen induced arthritis (CIA)
[4]. It has been demonstrated that overexpression of
CD154 (CD40L) on T cells correlates with higher disease
activity [5], which is confirmed by studies showing treat-
ment of mice with agonistic anti-CD40 Abs at the time of
CIA induction exacerbates disease [6]. Conversely,
administration of antagonistic anti-CD154 monoclonal
antibody (mAb) prior to induction of CIA ameliorates the
disease [7]. Suppression of the CD40-CD154 interaction
has been shown to actually induce generation of T regula-
tory (Treg) cells [8]. Despite promising preclinical data,
translation of CD40/154 blockade approaches has proved
difficult due to the expression of CD154 on platelets,
which causes risk of thromboembolic events. Accord-
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ingly novel methods of manipulating this interaction
without evoking platelet reactions are needed.
Since the DC acts as the most potent APC, we have pre-
viously used siRNA to manipulate expression of immuno-
logical genes in antigen pulsed DCs to either upregulate
or suppress immune responses in a specific manner
[9,10]. However, ex vivo cellular manipulation is imprac-
tical for widespread use. In addition, numerous autoanti-
gens are involved in clinical autoimmune diseases, thus
adding another layer of complexity in terms of clinical
development. Since CTLA4-Ig mediated co-stimulatory
blockade induces remission of autoimmunity, we sought
to determine whether a temporary suppression of CD40
expression by administration of siRNA may induce
i m m u n e  m o d u l a t o r y  e f f e c t s  o n  R A  t h a t  p r e d i s p o s e
towards reduction of immunity towards the autoantigen.
Such an approach is based on the concept that a transient
interruption of ongoing T cell activation during the initi-
ation and progression of the autoimmune process may
allow the host to default to a state of tolerance to the
autoantigen.
In this study, we used a hydrodynamic protocol to sys-
temically administer siRNA targeting CD40 in mice
before and after administration of autoreactive antigen.
We demonstrated antigen-specific immune modulation,
as well as both inhibition of arthritic disease. These data
support the possibility of temporary immune modulation
in the context of autoimmunity.
Materials and methods
Animals
Male DBA/1 LacJ and BALB/c mice (The Jackson Labo-
ratories, Bar Harbor, ME, USA), five weeks of age, were
kept in filter-top cages at the Animal Care and Veterinary
S e rvi c e s  F a c i l i t y  a t  t h e  U n i v e r s i t y  o f  W e s t e r n  O n t a r i o ,
according to the Canadian Council for Animal Care
Guidelines. Mice were fed food and water ad libitum and
allowed to settle for two weeks before initiation of experi-
mentation, which had ethical approval from the univer-
sity review board.
CIA Model
DBA/1 LacJ mice, seven weeks of age, were intradermally
immunized (Day 0) at the base of the tail with 200 μg of
bovine type II collagen (CII) (Sigma-Aldrich, St. Louis,
MO, USA) with complete Freund's adjuvant (CFA)
(Sigma). On Day 21 after priming, the mice received an
intraperitoneal booster injection with 200 μg. Mice were
examined visually three times per week for the appear-
ance of arthritis in the peripheral joints, and an arthritis
score index for disease severity was given as follows: 0 -
no evidence of erythema and swelling; 1 - erythema and
mild swelling confined to the mid-foot (tarsals) or ankle
joint; 2 - erythema and mild swelling extending from the
ankle to the mid-foot; 3 - erythema and moderate swell-
ing extending from the ankle to the metatarsal joints; 4 -
erythema and severe swelling encompassing the ankle,
foot, and digits. The maximum possible score per mouse
was 16. The severity of the arthritis was also determined
by the quantification of the paw swelling measured with a
dial gauge caliper. Scoring was done by two independent
observers, without knowledge of the experimental and
control groups.
DC Cultures
DCs were generated from bone marrow progenitor cells
as previously described [11]. Briefly, DCs were cultured
from bone marrow cells in six-well plates (Corning Inc.,
Corning, NY, USA) at 4 × 106 cells/well in 4 mL of RPMI
1640 medium supplemented with 2 mM L-glutamine,
100 U/ml penicillin, 100 μg of streptomycin, 50 μM 2-
ME, and 10% Fetal calf serum (FCS) (all from Invitrogen,
Mississauga, Ontario, Canada). Recombinant granulocyte
macrophage clony-stimulating factor (GM-CSF) (10 ng/
mL; PeproTech, Rocky Hill, NJ, USA) and recombinant
mouse interleukin 4 (IL-4) (10 ng/mL; PeproTech) were
added to the culture medium as growth factors. All cul-
tures were incubated at 37°C in 5% humidified CO2. Non-
adherent cells were removed after 48 h of culture (Day 2)
and fresh medium was added every 48 h.
siRNA design and gene transfection
siRNA sequence (TGTTCCACTGGGCTGAGAA), spe-
cifically targeting the CD40 gene, was designed and syn-
thesized by Dhmarcon (Dharmacon, Inc., Chicago, IL,
USA). CD40 siRNA-expressing vectors were generated
using the Silencer Express Kit (Ambion Inc, Austin, TX,
USA).
DCs (106cells/well) were plated in a 12-well plate one
day before transfection. On Day 6, 3 μl of 20 μM annealed
CD40 siRNA and 5 μL of transfect reagent Genesilener
(Gene Therapy Systems, San Diego, CA, USA) were sepa-
rately diluted with 50 μL serum-free medium RPMI 1640,
and then mixed rapidly and incubated at room tempera-
ture for five minutes to form a complex. The above
siRNA-Genesilencer complex was added to the DCs. GL2
siRNA was used as a negative control. After four hours
incubation, an equal volume of RPMI 1640 (500 μl) sup-
plemented with 20% FCS, 20 ng/mL GM-CSF and 20 ng/
mL IL-4 was added to the cells. Twenty-four hours after
transfection, cells were collected to determine gene
expression in DCs.
Administration of siRNA
DBA/1LacJ mice were treated with CD40 siRNA or con-
trol siRNA on Day -2 or Day 2 using a hydrodynamic
method [12]. In brief, 50 μg siRNA was diluted in 1 mlZheng et al. Arthritis Research & Therapy 2010, 12:R13
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Phosphate buffered saline (PBS) and quickly injected into
mice via tail veil in 10 s.
Mixed Leukocyte Reaction (MLR)
At Day 6 of culture, bone marrow-derived DCs from
DBA/1 LacJ mice were transfected with CD40 siRNA or
control siRNA. Transfected DCs were irradiated (3,000
rad) and seeded in triplicate in a flat-bottom 96-well plate
(Corning) for use as stimulator cells. Spleen T cells from
B A L B / c  m i c e  w e r e  i s o l a t e d  b y  g r a d i e n t  c e n t r i f u g a t i o n
over Ficoll-Paque (Amersham Pharmacia Biotech, Mon-
treal, Quebec, Canada) and added as responders (2 × 105
cells/well). The mixed lymphocytes were cultured at 37°C
for 72 h in 200 μL of RPMI 1640 supplemented with 10%
FCS, 100 U/ml of penicillin, and 100 μg/mL of streptomy-
cin and pulsed with 1 μCi/well of 3H-labelled thymidine
(Amersham Pharmacia Biotech) for the last 18 h of cul-
ture. Finally, cells were harvested onto glass fiber filters
(Perkin Elmer Life Science, Turku, Finland), and the
radioactivity incorporated was measured using a Wallac
Betaplate liquid scintillation counter (Beckman, Fuller-
ton, CA, USA). Results were expressed as mean counts
per minute of triplicate cultures ± SEM.
CII-specific T cell response
T cell responses to CII in subsequent groups of mice were
measured by 3H -thymidine incorporation in the pres-
ence of CII. T cells were isolated from spleen and lymph
node by gradient centrifugation over Ficoll-Paque (Amer-
sham Pharmacia Biotech). Unfractionated lymph node
cells were cultured in 96-well plates at a concentration of
2 × 105 cells/well for 72 h in the presence or absence of
CII antigen. Cells were cultured for two days, and then
cells were pulsed with 1 μCi of 3H-thymidine (Amersham
Pharmacia Biotech) for another 18 h of culture. Cells
were harvested onto glass fiber filters, and incorporated
radioactivity was quantified using a Wallac Betaplate liq-
uid scintillation counter.
Anti-CII antibody measurement
CII-specific Abs were detected using a standard indirect
ELISA in which 500 ng of CII was absorbed to each well
of a 96-well microtitre plate. Serial dilutions of immune
mouse serum were added to the appropriate wells in
duplicates and incubated overnight at 4°C. Dilutions of
serum were 1:100 to 1:10,000. To develop the ELISA,
horseradish peroxidase-conjugated goat anti-mouse IgG
Fc and ortho-phenylenediamine dihydrochloride sub-
strate buffer (Sigma) were used. An OD into each well
was measured at 450 nm wavelength in an ELISA plate
reader (Bio-Rad, Hercules, CA, USA).
Cytokine quantification
CD40 siRNA- or control siRNA-transfected DCs derived
from DBA/1 LacJ mice were cultured with the allogeneic
(BALB/c) T cells or alone for 48 h. The supernatants were
collected and examined for cytokines IL-2, IFN-γ and IL-
4) by ELISA. Cytokine-specific ELISA (Endogen, Rock-
ford, IL, USA) was used for detecting cytokine concentra-
tions in culture supernatants according to the
manufacturer's instructions using a Benchmark
Microplate Reader (Bio-Rad Laboratories Ltd., Missis-
sauga, ON, Canada).
Histology
P a w s  f r o m  e x p e r i m e n t a l  a n d  c o n t r o l  g r o u p s  o f  f r e s h l y
dissected mice were removed and joint tissues were
immersion-fixed in buffered formalin in 0.15 M PBS (pH
7.4) and decalcified with 5.5% EDTA. The specimens
were processed for paraffin embedding in paraplast
(BDH, Poole, Dorset, UK) as routine procedure. Serial
paraffin sections throughout the joint were cut at 5 μm
thickness on a microtome. Sections were stained with
haematoxylin and eosin (H&E) for assessment of histo-
logical damage. The severity of joint damage was scored
in a blinded manner as follows: 0 = normal, 1 = moderate
infiltration with discrete erosions, 2 = severe infiltration
and moderate erosions with preserved joints structure,
and 3 = severe erosions with loss of joint architecture.
Flow cytometry
Phenotypic analysis of DC was performed using flow
cytometry on a FACScan (Becton Dickinson, San Jose,
CA, USA). The cells were stained with FITC-, PE- or PE-
cy5-conjugated mAbs against surface markers associated
with DC maturation, these include: anti-mouse CD11c,
anti-mouse CD40, anti-mouse CD80 (Cedarlane Labora-
tories, Mississauga, ON, Canada). Tregs were analyzed by
triple staining with mAb against with Foxp3-FITC,
CD25-PE, and CD4-CY5, followed by flow cytometry
analysis. Ig of the same isotype was used as a control.
Statistical analysis
Data are expressed as mean ± SEM. Differences between
different groups of mice were compared using the Stu-
dent t-test for gene expression, antibody, cytokine and
histological scores or the Mann-Whitney U test for non-
parametric data. A P-value less than 0.05 was considered
significant.
Results
Knockdown of CD40 reduces allogenicity in DCs
Immature DCs are characterized by relatively low expres-
sion of stimulatory signals and higher levels of inhibitoryZheng et al. Arthritis Research & Therapy 2010, 12:R13
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signals to T cells [13]. Previously we demonstrated feasi-
bility of manipulating such signals using siRNA on DCs
in order to generate immunomodulatory DCs in a repro-
ducible manner by silencing IL-12p35 [14]. We have pos-
tulated that specific gene knock-down may be a more
attractive and defined means of immune modulation as
opposed to chemically generated immature DCs, which
we have also demonstrated to inhibit disease progression
in CIA [15]. Here we sought to develop inhibitory DCs
through gene silencing of CD40. DCs were generated
from bone marrow progenitors by standard IL-4 and
GM-CSF culture and transfected on Day 6 with CD40-
siRNA. Specific knockdown of CD40 mRNA and protein
was seen in DCs by RT-PCR (Figure 1A), and flow cytom-
etry (Figure 1B), respectively, as compared to DCs trans-
fected with control scrambled siRNA. Silencing was
specific in that CD 40 siRNA did not change gene expres-
sion of CD80 in DCs (Figure 1C).
Stimulation of T cell responses by DCs requires TCR
engaging molecules (MHC) and co-stimulatory mole-
cules CD40 [16]. CD40 is a critical co-stimulatory mole-
cule, thus knockdown of this molecule may impair DC's
ability to activate T cell response. To test this hypothesis,
we used CD40-silenced DCs as allostimulators in MLR.
As seen in Figure 1D, CD40-silenced DCs exhibited
markedly inferior allostimulatory activity as compared to
control DCs.
In vivo immunomodulation by administration of CD40 
siRNA
Our previous findings in other systems suggest that
m a n i p u l a t i o n  o f  D C  c o - s t i m u l a t o r y  m o l e c u l e s ,  e i t h e r
with chemicals [15] or siRNA [14,17] provides a simple
and reproducible method of in vivo inducing antigen-spe-
cific immune deviation. We sought to test the feasibility
of immunomodulation with CD40 knockdown in the CIA
model. However, unlike our previous experiments in
which CD40 knockdown was performed ex vivo on anti-
gen-pulsed DC to induce immune deviation [10], here
siRNA to CD40 was systemically administered two days
prior to immunization with CII. Using the hydrodynamic
injection method, 50 μg of siRNA was administered via
the tail vein two days before immunization. Proliferative
recall response to CII was performed to assess modula-
tion of T cell activation under the cover of CD40 silenc-
ing. T cells isolated from lymph nodes (Figures 2A) and
spleens (Figures 2B) exhibited reduced proliferation from
animals pretreated with CD40 siRNA but not controls. In
contrast, no modulation of response to T cell activation
with anti-CD3/CD28 in vitro was observed, indicating
that immune modulation was not associated with unspe-
cific T cell suppression (data not shown).
Blockage of the CD40-CD154 interaction has been
reported to alter cytokine production [16]. We sought to
assess whether flooding  the mice with CD40 siRNA
would affect cytokine differentiation. Treatment with
CD40 siRNA remarkably inhibited Th1 recall response,
as evidenced by decreased IL-2 (Figure 2C), and IFN-γ
(Figure 2D). The Th2 cytokine IL-4 was increased in the
mice treated with CD40 siRNA (Figure 2E). These data
imply that siRNA treatment induces immune modulation
in vivo including suppression of CII-Ag-specific T cell
responses as well as suppression of Th1 differentiation.
Prevention of autoimmune arthritis by treatment with 
CD40 siRNA
In previous studies we demonstrated that chemical
manipulation in DCs through inhibition of IKK, which is
responsible for CD40 upregulation in DC, can result in
generation of antigen-specific immune regulation and
suppression of pathology in the CIA model [15]. Here we
tested whether the systemic administration of CD40
siRNA may have a similar effect. DBA mice were treated
with a dose of 50 μg CD40 siRNA two days before immu-
nization with CII antigen and subsequently CD40 siRNA
was administered on Day 7 after immunization with CII.
After a boost immunization on Day 21, onset of CIA was
assessed. The disease onset occurred around Day 28 in
control siRNA treated group, versus Day 35 in CD40
siRNA treated group, as judged by erythema and swelling
of joints. Inhibition of arthritis clinical score was
observed in the mice treated with CD40 siRNA, as
opposed to control siRNA-treated mice which exhibited
no inhibition (Figure 3A). Additionally, the degree of joint
swelling was remarkably attenuated (Figure 3B) in the
mice treated with CD40-siRNA. These data suggest that
systemic administration of CD40 siRNA may prevent
autoimmune arthritis.
Intervention of autoimmune arthritis by treatment with 
CD40 siRNA
In order to explore the protective effect of CD40 siRNA
for potential clinical use, we treated mice at the stage of
post-initiation of the autoimmunity. Experimentally, DBA
mice were treated with CD40 siRNA two days after CII
immunization and repeated administration of siRNA two
weeks after first treatment. The average day of disease
onset was 31 days in the mice treated with CD40 siRNA.
After treatment with CD40 siRNA, the disease score was
significantly reduced as compared with mice treated with
control siRNA (Figure 4A). Furthermore, the joints were
less severe with decreased swelling of the joints (Figure
4B). These data suggested that siRNA may possess pro-
tective effects in a post-immunization stage of autoim-
mune arthritis.Zheng et al. Arthritis Research & Therapy 2010, 12:R13
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Histological assessment
To confirm the therapeutic effects of CD40 siRNA, we
next examined pathological changes in joints of CIA
mice. We observed that control mice displayed severe
bone erosion, pannus formation, and synovitis (Figure
5A). Furthermore, in control mice a marked neutrophilic
and mononuclear cell infiltration was seen. In contrast,
joints in mice treated with CD40 siRNA revealed, in most
cases, markedly attenuated morphological changes and
cellular infiltration, and the preservation of normal-
appearing cartilage (Figure 5B). The average histological
score was much lower in the group treated with CD40
siRNA as compared to the control siRNA group (Figure
5C).
Knockdown of CD40 reduces allogenicity in DCs
Figure 1 Knockdown of CD40 reduces allogenicity in DCs. DBA-derived DCs were cultured as described in Materials and methods. DCs were trans-
fected with CD40 siRNA using Genesilencer. Forty-eight hours after gene silencing, reduced gene expression of CD40 was detected by RT-PCR a) and 
flow cytometry b), respectively, without affecting CD80 gene expression determined by flow cytometry c). CD40-silenced DCs were also used to co-
culture allogeneic (BALB/c) T cells. T cell proliferation was assessed in MLR d). Data are presented as mean ± SEM. Results represent one of three exper-
iments. * = P < 0.05 versus control siRNA.Zheng et al. Arthritis Research & Therapy 2010, 12:R13
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Reduced CII antibody production and generation of Treg by 
treatment of CD40 siRNA
In order to dissect the mechanisms underling the preven-
tion and treatment of autoimmune arthritis by CD40
s i R N A ,  w e  a n a l y z e d  a n t i b o d y  l e v e l s  i n  t h e  C I A  m i c e
treated with CD40 siRNA. The reduction of CII antibody
production was observed in the groups treated with
CD40 siRNA either before immunization with CII (Fig-
ure 6A) or post immunization with CII (Figure 6B).
Furthermore, CD40 siRNA can inhibit immune
response in vitro (Figure 1) and in vivo (Figure 2), which
could be induced by an active immune suppression
through Treg cells. To test this hypothesis, we assessed
Treg cells in the CIA mice that were treated with CD40
siRNA or control siRNA. Treatment with CD40 siRNA
In vivo immunomodulation by administration of CD40 siRNA
Figure 2 In vivo immunomodulation by administration of CD40 siRNA. a) and b): CII-specific T cell responses by CD40 siRNA. DBA mice (seven 
mice per group) were injected with 50 μg of CD40 siRNA or control siRNA using hydrodynamic injection method. Two days after siRNA treatment, 
mice were immunized with 200 μg CII antigen. T cells from lymph nodes (A) and spleens (B) were isolated from the mice treated with CD40 siRNA or 
control siRNA. The antigen-specific T cells responses were assessed in the presence of CII. T cell proliferation was determined by 3H-incorporation 
assay, as described in the Materials and Methods. c), d) and e): The differentiation by CD40 siRNA. The supernatants from above cultures were harvest-
ed. The cytokines of IL-2 (C), INF-γ (D) and IL-4 (E) produced by T cells in the CII-specific response were detected by ELISA, as described in Materials 
and methods. Data are presented as mean ± SEM. Results represent one of three experiments. * = P < 0.05 versus control siRNA.Zheng et al. Arthritis Research & Therapy 2010, 12:R13
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enhanced CD4+CD25+Foxp3+ Treg cells generation (Fig-
ure 6C). These data imply that T reg may contribute to
immune modulatory effects of CD40 siRNA therapy.
Discussion
This report is the first to our knowledge to describe sys-
temic inhibition of CD40 by siRNA as a means of inter-
rupting autoimmune processes in order to up-regulate
the natural tendency of the immune system to re-equili-
brate tolerogenic mechanisms. We observed that admin-
istration of siRNA targeting CD40 could induce in vivo
inhibition of proliferative and cytokine recall response to
the joint antigen CII, as well as prophylactically inhibit
disease. Mechanistically it appeared that induction of
Treg cells was associated with suppression of autoimmu-
nity.
The CD40-CD154 interaction is involved in the initia-
tion of CIA. The major approach to intervening in this
interaction has been use of CD154-specific blocking
mAbs, which prevent T cell priming. This therapy is
highly effective in mouse models [4,18], although the
overall benefit of interruption of CD40-CD154 associa-
tion is reduced when Abs is administrated after disease
establishment. However, anti-CD154 treatment prevents
relapses of ongoing disease [18]. Despite the great prom-
ise displayed for CD154 Abs in a mouse CIA model, a
Preventing autoimmune arthritis by CD40 siRNA
Figure 3 Preventing autoimmune arthritis by CD40 siRNA. DBA 
mice (seven mice per group) were injected with 50 μg of CD40 siRNA 
or control siRNA using the hydrodynamic injection method. Two days 
after siRNA treatment, mice were immunized with 200 μg CII antigen, 
two times on Day 0 and Day 21, respectively. Treatment of CD 40 siRNA 
was repeated on Day 7 after first CII immunization. Disease severity was 
scored from the day of last immunization to five weeks a). The swelling 
of joints of CIA mice was determined by the thickness of each hind 
paw measured with caliper b). Data are presented as mean ± SEM. Re-
sults represent one of three experiments. * = P < 0.05 versus control 
siRNA.
Attenuated disease development by CD40 siRNA
Figure 4 Attenuated disease development by CD40 siRNA. DBA 
mice were immunized with 200 μg CII antigen, two times on Day 0 and 
Day 21, respectively. Two days after CII immunization, the mice were 
treated with 50 μg of CD40 siRNA using the hydrodynamic injection 
method. siRNA treatment was repeated two weeks later. Disease sever-
ity was scored from the day of last immunization to five weeks a). The 
swelling of joints of CIA mice was determined by the thickness of each 
hind paw measured with caliper b). Data are presented as mean ± 
SEM. Results represent one of three experiments. * = P < 0.05 versus 
control siRNA.Zheng et al. Arthritis Research & Therapy 2010, 12:R13
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particular challenge in clinical use has been thromboem-
bolism [4,18]. Another approach has been the use of
blocking peptides. Unfortunately, this approach was
restricted by the high concentrations needed for in vivo
effects [19]. Using mAbs against CD40 such as the anti-
human CD40 antagonist mAb, ch5D12, showed promise
in autoimmune disease. New intervention strategies that
spare normal immune function while blocking damaging
effects of CD40 signaling are desirable. RNA inference
may provide a novel approach to blocking the CD40 sig-
nal.
In the area of tolerance induction, numerous
approaches have been attempted, however, to our knowl-
edge, none have passed registration trials. Strictly anti-
gen-specific approaches are deficient because in many
situations numerous autoantigens contribute to disease.
In the context of RA, while CII is sufficient to induce an
RA-like disease in animal models, multiple proteins have
been implicated in the human RA [1]. Examples of
autoantigens in human RA include citrullinated fibrino-
gen, hsp47 and 60 [20,21]. The second problem is that
induction of Ag-specific tolerance can only be achieved
by limited means even if antigens are known; for example,
oral tolerance [22], intravenous tolerance, or as we previ-
Histological changes in CIA mice after treatment with CD40 siRNA
Figure 5 Histological changes in CIA mice after treatment with 
CD40 siRNA. At the end point of observation, mice were sacrificed. 
The joints from the mice treated with CD40 siRNA a) and control siRNA 
b) were collected, fixed, and stained with H&E. The hisopathological 
change was scored c). Original magnification × 100. Results are repre-
sentative of seven mice.
In vivo immune modulation by CD40 siRNA
Figure 6 In vivo immune modulation by CD40 siRNA. a) and b) In-
hibition of CII-specific antibody production in arthritis mice following 
CD40 siRNA. DBA mice were immunized with CII antigen and treated 
with CD40 siRNA or control siRNA, as described in Figure 3 or Figure 4. 
Sera were collected at the end point of experiments (five weeks after 
second immunization). The CII-specific antibodies from the mice in 
Figure 3 (A) and in Figure 4 (B) were detected by ELISA, as described in 
Materials and methods. c). Generation of Treg in arthritis mice follow-
ing CD40 siRNA. DBA mice were immunized with CII antigen and treat-
ed with CD40 siRNA or control siRNA, as described in Figure 3. T cells 
were harvested from lymph nodes in the mice at the end point of ex-
periments (five weeks after the second immunization). T cells were 
stained with mAbs against CD4, CD25 and Foxp3, respectively, and an-
alyzed by flow cytometry. Results represent one of three experiments.Zheng et al. Arthritis Research & Therapy 2010, 12:R13
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ously published, ex vivo pulsing of DCs with autoantigen.
These methods are either not practical or weakly effec-
tive.
The method used in the current study is based on our
previous observations that manipulation of CD40 on DC
can be tolerogenic [10,23]. Accordingly, we sought to
determine if systemic inhibition through flooding the
body with siRNA can achieve a therapeutic effect. This
method has several drawbacks: First, hydrodynamic
administration is clinically impossible. Second, while we
demonstrated inhibition of disease, complete tolerance
was not achieved. Third, the possibility of non-specific
immune suppression during administration of CD40
siRNA is a possibility. There are ways to address these
concerns which will be studied in subsequent experi-
ments. We previously reported successful administration
of nanoparticles containing siRNA to DCs by the use of
DEC-205 antibody coated immunoliposomes [23]. By
selectively delivering the immune modulatory siRNA to
the targeted DCs, it may be feasible to circumvent the
clinical barriers associated with hydrodynamic adminis-
tration. While complete inhibition of disease was not
observed, the finding that administration of siRNA even
after disease initiation occurred was effective suggests
that the temporary CD40 inhibition may have potent
therapeutic effects. While it is tempting to suggest multi-
ple administrations, this would risk the possibility of
compromising immunity towards pathogenic agents, as
seen with the TNF-inhibitors causing reappearance of
infectious diseases such as tuberculosis. One method of
avoiding the need for multiple immune suppressions may
involve co-immunization of a recipient with autoantigens
under the cover of CD40 siRNA. This may be one
method of recycling  previously tried antigen-specific
agents that demonstrated some efficacy in clinical trials
but were not sufficient to warrant marketing approval.
It is recognized that CD40 is expressed by B cells, mac-
rophages, and some T cells. The effects seen after inhibi-
tion of CD40 might be attributable to a direct effect on
CD40 in B cells or an indirect effect through lower activa-
tion of T cells. We consider that one attractive possible
mechanism by which systemic CD40 inhibition mediates
immune modulation is through the up-regulation of Treg
cells. We have demonstrated increased numbers of Treg
cells in CD40 siRNA treated mice. It is conceptually
appealing to ask whether these Treg cells arise due to the
presence of autoantigen in the absence of co-stimulatory
molecules. Indeed, DCs in RelB knockout mice, which
lack CD40, have been demonstrated to induce infectious
tolerance through induction of Treg cells [24].
Conclusions
In conclusion, we have demonstrated a simple and easy to
induce a method of selectively inhibiting disease progres-
sion in the CIA model of RA through systemic adminis-
tration of CD40 siRNA. The possibility of using such
semiselective methods of immune modulation which do
not require long-term administration may be a more nat-
ural and easily tolerated means of treating autoimmune
disease than current techniques in which immune modu-
lators are given on a continuous basis.
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